Statistical Analysis

AH Afef Ben Halima
SO Sana Ouali
MM Mohamed Sami Mourali
SC Sonia Chabrak
RC Rafik Chettaoui
MH Manel Ben Halima
AH Abdeddayem Haggui
NL Noureddine Larbi
SK Salma Krichène
SM Sonia Marrakchi
SK Slim Kacem
RC Rim Chrigui
MA Mohamed Fahmi Abbes
HB Hédi Baccar
NB Nadia Baraket
NH Najeh Ben Halima
AK Ali Ben Khalfallah
MM Mohamed Ben Mbarek
SY Soraya Ben Youssef
EB Essia Boughzala
MB Mohamed Rachid Boujnah
HD Habiba Drissa
HG Habib Gamra
AG Ali Gasmi
HH Habib Haouala
YH Youssef Harrath
II Ines Issa
GJ Gouider Jeridi
SK Salem Kachboura
SK Samir Kammoun
SK Sondes Kraiem
FM Faouzi Maatouk
SM Sami Milouchi
WN Wided Nasraoui
AN Ali Neji
KS Khaled Sayahi
WS Wissem Sdiri
WS Wajih Smati
ST Samir Tlili
LA Leila Abid
SA Salem Abdesselem
LZ Lilia Zakhama
AM Abdallah Mahdhaoui
HK Helmi Kammoun
SO Skander Ben Omrane
FA Faouzi Addad
request Request a Protocol
ask Ask a question
Favorite

Continuous variables will be described by mean and standard deviation or as median and interquartile range. Categorical variables will be described by the size and frequency of every modality. Means comparison will be performed by analysis of variance or by nonparametric tests if the hypothesis of normality is rejected. The normality of continuous variables will be verified with the Shapiro-Wilk test. The statistical tests are bilateral with a 95% confidence interval.

A chi-square test will be performed for categorical variables. Yates correction or the Fisher exact test will be used if the conditions of validity for the chi-square test are not met.

A multivariate analysis will be performed with anticoagulant treatment (over or undertreated) as dependant factor. The independent variables will be age, gender, body mass index, type of AF, combined therapy. Univariate logistic regression will be carried out with a 10% output threshold. The final model will be performed with the parameters selected by the backward stepwise method of Wald. The selected variables in the final model will be tested at the 5% threshold. The interaction between selected parameters is tested at the 10% threshold.

The TTR will be calculated by the method first described by Rosendaal et al [8], which uses linear interpolation of INR values in each patient under oral anticoagulant treatment to calculate the percentage of days when the INR is in the therapeutic range (2.0-3.0) for nonvalvular AF.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A